Evotec appoints Rui Wang AI Head
Analysis based on 8 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026
The appointment of Wang Rui>>> is expected to positively impact Evotec>>>'s stock price due to the enhanced focus on AI-driven drug discovery, which could lead to more efficient and innovative development of new therapies. This strategic move signals Evotec>>>'s commitment to leveraging advanced computational tools, potentially increasing its competitive edge in the biotechnology and pharmaceutical industries.
Evotec>>> announced the appointment of Wang Rui>>> as Executive Vice President, Head of Global In Silico and AI on June 2, 2026. Wang Rui>>> brings over 20 years of experience in embedding scalable data, analytics, and AI across R&D, drug development, manufacturing, and supply chain functions in global pharma and biotech organizations. His previous roles include Head of Data, Analytics and AI at AstraZeneca>>>, and positions at the European Bioinformatics Institute (part of European Molecular Biology Laboratory>>>) and Tangram Therapeutics>>>. Wang Rui>>> holds M.Sc. degrees from the University of Manchester and Newcastle University. In his new role, he will lead the integration of computational science and data-driven decision-making across Evotec>>>'s R&D operations, aiming to make AI and in silico science key pillars of the company's commercial value proposition. Christian Wojczewski>>>, CEO of Evotec>>>, emphasized that Wang Rui>>>'s role is crucial for making Evotec>>>'s drug discovery and development enterprise a powerful engine of innovation, integration, and operational efficiency, particularly for its Drug Discovery and Preclinical Development and Just - Evotec Biologics segments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard